NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
---|---|---|---|---|---|
Total Liabilities | ₹1,026 Cr | ₹880 Cr | ₹793 Cr | ₹739 Cr | ₹157 Cr |
What is the latest Total Liabilities ratio of NATH BIOGENES (INDIA) ?
Year | Total Liabilities |
---|---|
Mar2025 | ₹1,026 Cr |
Mar2024 | ₹880 Cr |
Mar2023 | ₹793 Cr |
Mar2022 | ₹739 Cr |
Mar2013 | ₹157 Cr |
How is Total Liabilities of NATH BIOGENES (INDIA) Trending?
Years | Total Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹1,026 Cr | 16.58 | |
Mar2024 | ₹880 Cr | 11.03 | |
Mar2023 | ₹793 Cr | 7.21 | |
Mar2022 | ₹739 Cr | 369.87 | |
Mar2013 | ₹157 Cr | - |
Compare Total Liabilities of peers of NATH BIOGENES (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATH BIOGENES (INDIA) | ₹330.6 Cr | -1.2% | -4% | -22.7% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹12,564.5 Cr | -2.2% | -6.1% | -30.2% | Stock Analytics | |
KAVERI SEED COMPANY | ₹5,945.6 Cr | 0.3% | 4.3% | 7.5% | Stock Analytics | |
VENKYS (INDIA) | ₹2,078.0 Cr | -0.2% | -3.4% | -35.4% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,527.5 Cr | 7.8% | 8.8% | -28.5% | Stock Analytics | |
INDO US BIOTECH | ₹299.4 Cr | -0.8% | -6.8% | -41.8% | Stock Analytics |
NATH BIOGENES (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATH BIOGENES (INDIA) | -1.2% |
-4% |
-22.7% |
SENSEX | -2.2% |
-1.7% |
-1.2% |
You may also like the below Video Courses